News and Information

Company News

Industry News

Public service advertisement

2017 Analysis of the Development of China’s Medical Device Industry

In 2017, the two‑invoice system will transition from last year’s pilot program to full implementation. Large enterprises will deepen their distribution channels, while small and medium‑sized distributors will face elimination, consolidation, or transformation. Under this trend, the industry will give rise to three major structural shifts: horizontal acquisitions, vertical integration, and strategic transformation.

2017

08-05

Countries along the Belt and Road Initiative represent another major market for medical devices.

Recently, numerous medical device exhibitions have been taking place both domestically and internationally. With so many events on the calendar, you may be feeling overwhelmed. We’ve compiled a list of medical device trade shows scheduled for the second half of 2017, along with brief overviews of selected conferences, in hopes that this will prove helpful.

2017

08-15

Medical Devices: Domestic Manufacturers Oust Imports—These Four Key Sectors Show Promise!

Medical devices: Rapid growth is expected, with substantial room for import substitution. From an industry perspective, China’s medical device market has surpassed RMB 300 billion, making it the second-largest globally. However, medical device spending accounts for only 17% of the overall pharmaceutical market—just 40% of the level in developed countries. With population aging and rising health‑insurance reimbursement levels, the market is projected to expand by at least another 5 percentage points over the next five years, translating into additional market growth exceeding RMB 300 billion.

2017

10-27

Jointly Exploring the Path of Reform and Innovation in the Medical Device Industry

If the issuance of the “Opinions on Reforming the Review and Approval System for Drugs and Medical Devices” marked the beginning of reforms in this area, then the recently released “Opinions on Deepening the Reform of the Review and Approval System and Encouraging Innovation in Drugs and Medical Devices,” issued by the Two Offices, will further advance structural adjustments and technological innovation within the pharmaceutical and medical device industries.

2017

11-18

Medical device and pharmaceutical reform has expanded from review and approval to a transformation of the regulatory system.

Recently, the General Office of the CPC Central Committee and the General Office of the State Council jointly issued the “Opinions on Deepening the Reform of the Review and Approval System and Encouraging Innovation in Pharmaceuticals and Medical Devices” (hereinafter referred to as the “Opinions”). Following the August 2015 “Opinions of the State Council on Reforming the Review and Approval System for Pharmaceuticals and Medical Devices,” this document represents another landmark policy paper aimed at further advancing reforms of the review and approval system for pharmaceuticals and medical devices. It can be seen as a comprehensive summary and deepening of the two-year experience gained in reforming this system, as well as a concentrated embodiment of the strategic decisions and arrangements made by the CPC Central Committee and the State Council regarding the regulation of food and drugs.

2017

11-19

Xi Jinping: Implement the National Big Data Strategy and Accelerate the Development of Digital China.

On the afternoon of December 8, the Political Bureau of the CPC Central Committee held its second collective study session on implementing the National Big Data Strategy. While presiding over the session, General Secretary Xi Jinping emphasized that big data is advancing at a rapid pace, and that we must assess the situation, plan carefully, make forward‑looking arrangements, and strive to take the initiative. He called for a deep understanding of the current state and trends of big data development and its impact on economic and social progress, an analysis of both the achievements and the challenges facing China’s big data sector, and vigorous efforts to implement the National Big Data Strategy—accelerating the improvement of digital infrastructure, promoting the integration and open sharing of data resources, ensuring data security, and speeding up the building of a Digital China to better serve the country’s economic and social development and enhance the well‑being of the people.

2017

12-09

< 1...789...13 >

30 Years of Cultivation and Development

The “Hongda” brand products manufactured by the Group encompass eight major categories of medical devices, including syringes, infusion (and blood) sets, puncture instruments, auxiliary diagnostic equipment, anesthesia supplies, catheters, comprehensive solutions for blood purification, and multimodal smart healthcare information management systems.

Entering Hongda

Company Profile
Honors and Qualifications
Corporate culture

News Center

Company News
Industry News

Public service advertisement

Product Center

Infusion blood sets
Syringe category
Puncture Instrument Category
Inspect medical devices

Medical protective category
Anesthesia Catheter Category
Hemodialysis consumables
Electronic medical devices

Scan the code to follow our official account.

Friendly Links:China Civilization Website | Jiangxi Civilization Website | Nanchang Civilization Website

Copyright © 2026 Jiangxi Hongda Medical Device Group Co., Ltd. All rights reserved.

Website Development:China Enterprise Dynamics Nanchang SEO